SGI Awarded $27M Systems Contract with the Army Research Laboratory Defense Supercomputing Resource Center
MILPITAS, Calif., 2016-11-01 00:46 CET (GLOBE NEWSWIRE) -- Today, SGI (NASDAQ:SGI), a global leader in high-performance solutions for compute, data analytics, and data management, announced that the United States Department of Defense (DoD) has selected SGI® ICE™ XA for two of its Army Research Laboratory Defense Supercomputing Resource Center (ARL DSRC) systems. The upgrades are part of a technology insertion, known as TI-16, for their High Performance Computing Modernization Program (HPCMP).
HPCMP delivers world-class commercial, high-end, high-performance computational capabilities to DoD’s Research, Development, Test and Evaluation (RDT&E) community through its five DoD Supercomputing Resource Centers (DSRCs).
With HPC technology, DoD scientists and engineers can utilize physics-based simulations to achieve better understanding of a variety of phenomena affecting national defense. The upgraded systems also allow quick data searches that are generated from field tests across a wide spectrum of military operations. Powerful supercomputers help with data quality, increasing situational awareness, and advancing soldier performance with live and virtual data analytics. The new SGI systems will be leveraged to scale algorithms, increase real-time experimental data processing and methods for live-virtual simulations.
The agreement for ARL DSRC system #1 values at $8.9 million, and ARL DSRC system #2 at $17.6 million.
SGI was also awarded four annual maintenance options over the next four years, allowing DoD to leverage its world-class professional services available 24/7. The work for both systems will be performed at Aberdeen Proving Ground, Maryland, with an estimated completion date of April 24, 2021. Army Corps of Engineers, Huntsville, Alabama, has been delegated contracting authority for these agreements.
- DoD has selected SGI to increase supercomputing power with two ARL DSRC systems
- DoD’s investment in supercomputers helps with data quality, increasing situational awareness, and advancing soldier performance with live and virtual data analytics; it also allows DoD scientists and engineers to achieve a better understanding of a variety of phenomena affecting national defense
- The upgraded SGI systems will help DoD scale algorithms, increase real-time experimental data processing and methods for live-virtual simulations
- ARL DSRC system #1 will deploy SGI® ICE™ XA with quad node blade and E-Cell technology, utilizing the 22-core Intel® Xeon® processor E5-2699 v4 to achieve peak compute power
- ARL DSRC system #1 will be comprised of 33,088 compute cores offering 1.16 Petaflops capability, a Mellanox Enhanced Data Rate (EDR) as a 1:1 non-blocking Fat-Tree with 3.4 PB usable storage based on SGI InfiniteStorage 5600i technology
- ARL DSRC system #2 will deploy SGI® ICE™ XA comprised of 73,920 Intel® Xeon® processor E5-2698 v4 compute cores, offering 2.6 Petaflops capability, a Mellanox Enhanced Data Rate (EDR)-based 1:1 non-blocking Fat-Tree and 11.8 PB usable storage based on SGI InfiniteStorage 5600i technology
"We’re excited to partner with SGI for our TI-16 DoD program, and have full confidence in the system’s ability to provide excellent performance," said Dr. Raju Namburu, director of ARL DSRC. “Choosing the right HPC partners is crucial, as we rely on supercomputing and large-scale analytics and predictive sciences to provide the competitive edge we need to maintain our position as the nation’s premier laboratory for land forces.”
"We believe that the two SGI systems will bring a unique capability to solve DoD's most challenging problems," said Thomas Kendall, technical director of ARL DSRC. "The combination of a non-blocking, fat-tree topology, based on the recently available 100 Gbps EDR technology and the newest server CPU technology will enable a wide range of applications to consistently achieve high levels of performance.”
"DoD’s annual, recurring investment in HPC is a testament to its belief in the power and strategic value of supercomputing,” said Jorge Titinger, president and CEO, SGI. “Expanding our partnership with ARL DSCR is the result of our record of exceptional HPC performance with previous DoD systems. We have had a healthy long-standing relationship with HPCMP over the last two decades, and we remain committed to delivering to DoD new innovative technology and the highest level of service and management. We look forward to continuing our partnership with one of the most important institutions in our nation.”
- Army Research Labs chooses @SGI_Corp #HPC system for latest HPCMP deployment @INTEL #supercomputer http://bit.ly/2e5Qtps
- ARL uses @SGI_Corp #supercomputer to scale algorithms increase real-time experimental data processing and methods for live-virtual simulations #HPC http://bit.ly/2e5Qtps
SGI is a global leader in high-performance solutions for compute, data analytics, and data management that enable customers to accelerate time to discovery, innovation, and profitability. Visit sgi.com (sgi.com/) for more information.
© 2016 Silicon Graphics International Corp. All rights reserved. SGI and the SGI logo are trademarks or registered trademarks of Silicon Graphics International Corp. or its subsidiaries in the United States and/or other countries. Intel and Xeon are trademarks or registered trademarks of Intel Corporation. All other product and service names mentioned are the trademarks of their respective companies.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30 | Pressemelding
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma
Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15 | Pressemelding
BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05 | Pressemelding
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public
Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00 | Pressemelding
OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to
Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29 | Pressemelding
ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern
Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30 | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom